Article

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

2024-10-11

Abstract excerpt

Immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy. However, given the limited number of current targets, the identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with limited normal tissue expression and high expression in multiple r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e88cd456-e8db-53c4-961a-4189e310ab5e
DOI: 10.1101/2024.10.09.617077

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinomaDOI 10.1101/2024.10.09.617077Read

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaSemantic proximity Read

Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinomaSemantic proximity Read

Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved OutcomesSemantic proximity Read

The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancerSemantic proximity Read

Adrenocortical cancer.Semantic proximity Read

Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.Semantic proximity Read

EMS1/DLL4-Notch Signaling Axis Augments Cell Cycle-Mediated Tumorigenesis and Progress in Human Adrenocortical CarcinomaSemantic proximity Read

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.Semantic proximity Read

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.Semantic proximity Read

Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.Semantic proximity Read

YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.Semantic proximity Read

Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging TherapiesSemantic proximity Read